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■ CLINICAL COMMENTARY:
When warfarin is started, 
aspirin should be stopped
The lack of evidence to support the combined
use of aspirin and warfarin creates an excellent
opportunity to remove an unnecessary drug
from a patient’s medication list. Patients who
were taking aspirin for thrombosis prophylaxis
occasionally develop atrial fibrillation. Many
patients who take aspirin for prophylaxis do so
because they are already at moderate to high
risk for embolic stroke. The onset of atrial fib-
rillation in these patients appropriately leads to
the initiation of warfarin. At the time of war-
farin initiation, the aspirin should be stopped.
By stopping the aspirin at the initiation of the
warfarin, one can reduce the number of med-
ications that the patient must take, avoid the
interactions of aspirin and warfarin, and elimi-
nate the side the effects of the aspirin.
Rick Guthmann, MD, Illinois Masonic Family Practice
Residency, University of Illinois at Chicago
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Do statins reduce 
the risk of stroke?
■ EVIDENCE-BASED ANSWER
HMG Co-A reductase inhibitors (statins) are effec-
tive for primary prevention of ischemic stroke in
people who have a history of occlusive artery dis-
ease, coronary artery disease, or diabetes without
history of cerebrovascular disease (strength of
recommendation [SOR]: A, based on 1 random-
ized controlled trial [RCT]).
Statins reduce the risk of ischemic stroke in
hypertensive patients with multiple cardiovascu-
lar risk factors and nonfasting total cholesterol
<250 mg/dL (SOR: A, based on RCT). Statins also
reduce the risk of ischemic stroke for patients
with coronary disease or equivalents (such as dia-
betes or peripheral artery disease), including
patients who have a normal fasting lipid profile
(SOR: A, based on RCT). For patients with
ischemic stroke who have coronary disease,
statins prevent recurrent ischemic stroke; evi-
dence is conflicting about whether this benefit is
proportional to initial cholesterol levels (SOR: A,
systematic review). Statins do not prevent hemor-
rhagic stroke (SOR: A, based on RCTs).
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■ EVIDENCE SUMMARY
We found no studies evaluating statins for the pri-
mary prevention of stroke. An observational study
of 433 patients with ischemic stroke found that
patients who were taking statins before hospital
admission more often had better outcomes (51%)
than those who were not taking statins (38%).
However, the groups differed in many respects.1
Many coronary event prevention and treatment
trials using statins include the risk of primary and
recurrent ischemic stroke as secondary endpoints
for patients with high cardiac risk. 
Primary prevention of stroke in vascular 
disease. The Heart Protection Study followed
20,536 patients in the United Kingdom (aged
40–80 years), 3280 with a history of cerebrovas-
cular disease (defined as nondisabling stroke,
transient cerebral ischemic attack, or carotid
endarterectomy or angioplasty) and 17,256 with
other occlusive arterial disease, coronary artery
disease, or diabetes. Patients were randomized to
receive either simvastatin 40 mg or placebo for an
average of 5 years. The endpoint was major vas-
cular events: myocardial infarction, stroke of any
type, and revascularization procedure. 
Simvastatin reduced the combined risk of non-
fatal or fatal ischemic stroke for patients with no
history of cerebrovascular disease (3.2% for sim-
vastatin vs 4.8% with placebo; relative risk reduc-
tion=33%, number needed to treat [NNT]=63;
P=.0001).2 As noted in other well-done studies, the
Heart Protection Study showed no difference in the
number of hemorrhagic strokes between treatment
and placebo groups. There were 3500 subjects with
pretreatment low-density lipoprotein (LDL) choles-
terol <100 mg/dL; lowering LDL to 65 mg/dL
reduced major vascular event risk by about 25%.3
Hypertension with multiple cardiovascular
risk factors and cholesterol <250 mg/dL. The
ASCOT-LLA study compared atorvastatin with
placebo in 10,305 hypertensive Caucasian
patients with multiple cardiovascular risk fac-
tors and a total nonfasting cholesterol of 250
mg/dL (6.5 mmol/L) or less. Patients were aged
40 to 79 years and had at least 3 other cardio-
vascular risk factors (left ventricular hypertro-
phy, abnormal electrocardiogram, type 2 dia-
betes, peripheral artery disease, stroke or tran-
sient ischemic attack, male sex, age >55 years,
proteinuria or microalbuminuria, smoking, fam-
ily history of premature coronary heart disease).
The study was stopped early at a median of 3.3
years because atorvastatin significantly reduced
cardiac events. Atorvastatin also significantly
reduced ischemic strokes when compared with
placebo (relative risk [RR]=0.73, 95% confi-
dence interval [CI], 0.56–0.96; P=.024). This
study did not differentiate between first or sec-
ond stroke. The NNT was 155.4
Ischemic stroke and coronary disease. The
LIPID trial randomized 9014 patients with a
history of acute coronary syndromes and total
cholesterol of 150 to 270 mg/dL (4 to 7 mmol/L)
to either pravastatin or placebo and followed
them for 6 years. Among the 350 patients with
prior ischemic stroke, there were 388 new
ischemic stokes over the course of the study.
When adjusted for risk factors (atrial fibrilla-
tion, history of cerebrovascular accident, dia-
betes, hypertension, cigarette smoking, body
mass index, and male sex), pravastatin reduced
recurrent ischemic stroke by 21% relative to
placebo (P=.024). The reduction was not modi-
fied by baseline lipid level.5
A meta-analysis of 15 randomized placebo-
controlled trials using various statins (32,684
participants) assessed the risk of strokes for
patients with a history of coronary disease.
Among patients who had cerebrovascular dis-
ease, statins significantly reduced recurrent
ischemic stroke (RR=0.74; 95% CI, 0.64–0.86).
One recurrence of ischemic stroke would be pre-
vented for every 110 coronary disease patients
treated with a statin. Achieving final total cho-
lesterol <232 mg/dL correlated with reduced
Statins reduce the risk of ischemic
stroke for patients with coronary
disease or equivalents
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risk of recurrent stroke.6 Three of the studies
evaluated primary prevention of stroke and did
not show a significant risk reduction (RR=0.85;
P=.4). Statins did not reduce the rate of hemor-
rhagic stroke or fatal strokes. 
Risks of statins. In 1 study involving 35,000
participants and 158,000 person-years of observa-
tion, there were 8 cases of rhabdomyolysis in the
treatment groups vs 5 in the placebo groups.7
Forty-three deaths attributed to statin therapy
have been reported to the Food and Drug
Administration from 1987 to 2001, or 1 per mil-
lion person-years of use. The Heart Protection
Study found simvastatin and placebo users report-
ed myopathy or muscle pain at the same annual
rate of 0.01%.
■ RECOMMENDATIONS FROM OTHERS
We found no recommendations specifically
regarding the use of statins to prevent stroke.
However, the Third Report of the National
Cholesterol Education Program, Adult Treatment
Panel III (NCEP-ATP III) describes symptomatic
carotid artery disease as a coronary heart disease
risk equivalent and recommends therapy to
reduce the LDL below 100 mg/dL.8
Naomi Busch, MD, Gary Kelsberg, MD,
Valley Family Medicine, Renton, WA; Susan K. Kendall,
PhD, MSLIS, Michigan State University
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■ CLINICAL COMMENTARY:
Statins prevent cerebrovascular accidents
and have low adverse event rates
Statins are effective for primary and tertiary
cardiovascular disease prevention. For those
with vascular disease or significant risks,
statins prevent cerebrovascular accidents and
have low adverse event rates. 
While no evidence is available about pri-
mary prevention of cerebrovascular accidents for
those at lower risk, in practice statins are often
appropriately initiated. NCEP-ATP III,8 the key
guideline on when to start statins, is based
more on cardiac benefits. Most studies evaluat-
ing statins use a triple outcome of mortality,
myocardial infarction, or cerebrovascular acci-
dent. Since myocardial infarction is more com-
mon than the other adverse endpoints, there is
a greater demonstrated cardioprotective effect
(prevention of myocardial infarction: NNT=95;
prevention of cerebrovascular accidents:
NNT=735).9 However, regardless of whether
the benefits are cardiac or cerebrovascular,
statins will prevent disease for many patients.
Alex Krist, MD, Fairfax Family Practice Residency,
Virginia Commonwealth University, Fairfax
